How We Build
Business
How We Build
Business
Creating long-term value is our goal. We help companies excel and develop what they do best, building sustainable market leaders that last beyond ARCHIMED’s investment horizon. Through our approach to strategic- and operational-value creation, we support Japanese and global healthcare companies to accelerate their growth and profit margin expansion.
+20%
Average Annual Topline Growth.
+30%
Average EBITDA Margin.
+60%
Growth Rate vs. Pre-ARCHIMED Performance.
Watch and see why CEOs choose ARCHIMED as their strategic partner.
Our Value
Creation
Levers
Innovation 
Investing in innovation is key to accelerating growth. At ARCHIMED, we take a tailored approach—supporting companies with investments in new technologies, enhanced R&D, and compliance or accreditation to strengthen their in-house capabilities.
“ARCHIMED’s support enables us to drive innovation and efficiency, enabling us to deliver cutting-edge solutions such as Brain Watch.”
CEO, NATUS
Business Development
ARCHIMED identifies opportunities across the healthcare market in Japan and internationally through its extensive network of leading companies and key opinion leaders, including those in niche sectors. By leveraging these connections, we foster strategic partnerships and drive innovation.
“ARCHIMED gave us the opportunity to gain real market insight from some of the industry’s most senior people, helping us shape our pricing strategy and become more competitive.”
CEO, Title21
Product & Service Range Expansion
By providing the right capital and strategic support, we help our companies accelerate the expansion of their products and services. ARCHIMED consistently increases R&D investment compared to pre-partnership levels.
“Thanks to ARCHIMED, we added viral clearance services to the biosafety testing product portfolio, complementing the offering and reinforcing Clean Cells’ leading position in biosafety testing.”
CEO, Clean Biologics
Internationalization
ARCHIMED’s international team leverages its global presence and experience to support companies’ international expansion, whether through organic growth or acquisitions, by building local sales forces, subsidiaries, or distributor networks in strategic markets.
“ARCHIMED’s international expansion expertise and local resources helped us globalize and expand our direct sales, making the US our largest market.”
Chairman, Polyplus
M&A and Add-On Acquisitions
Our network, pipeline, and capabilities help our companies pursue M&A and add-on acquisitions. On average, each ARCHIMED company completes two acquisitions, with some achieving up to fifteen.
“ARCHIMED’s strong network of companies, and a strong M&A and add-on track record had significant value for the growth of NAMSA.”
Vice Chair, NAMSA
Japan
Business
Cases
Nihon Koden JV
Partnering with Nihon Kohden to drive Ad-Tech’s future growth.
Sector
MedTech
Entry
November 2024
Business
Developers and distributors of medical electronic equipment
ARCHIMED Initiative
- Ongoing Collaboration Between ARCHIMED and Nihon Kohden Before and After the Ad-Tech Acquisition.
- Support for post-merger integration following Nihon Kohden’s acquisition of Ad-Tech.
- Advised on strategies to realize operational and business synergies.
- Support regulatory and compliance initiatives, including leveraging NAMSA.
“By uniting our strengths, we’re enhancing our ability to provide end-to-end support for epilepsy—from accurate diagnosis to advanced interventions.”
President, Nihon Kohden America
go back
Jeisys Medical
Providing critical support for long-term expansion and reinforcing its position in the international skincare market.
Sector
Consumer Health
Entry
September 2024
Business
Non–invasive aesthetic medicine devices for skincare
ARCHIMED Initiatives
- Take-Private Investment.
- Rapid establishment of the US entity with full staffing support.
- Aiming for next growth phase with founding family through long-term partnership.
- Reinforcing stable and complementary management.
- Strengthening collaboration between Japan and Korea HQ.
- Internationalization, leveraging synergies with other ARCHIMED companies; NAMSA supports US market entry and regulatory approval processes.
- M&A activities in Japan, Korea, and the US.
- Enhancing R&D investment.
“ARCHIMED’s regulatory expertise and existing distribution network through its companies are significant assets for our global market expansion.”
CEO, Jeisys
go back
Agatha
Transforming a Japanese leader into a global platform connecting healthcare institutions and pharmaceutical companies.
Sector
Healthcare IT
Entry
April 2025
Business
Clinical Trial Digital Transformation SaaS Provider
ARCHIMED Initiatives
-
- Expanding market share in 16 existing countries and accelerating global expansion, especially in Europe and North America.
- Leveraging AI-powered, data-driven approaches to strengthen R&D and product development.
- Expanding organizational capabilities by enhancing global talent acquisition and operations.
“By fully leveraging ARCHIMED’s expertise and global network, we will accelerate our growth as we work toward realizing a global platform that connects healthcare institutions and pharmaceutical companies worldwide.”
CEO, Agatha
go back